Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

Sanofi has been given a reprimand by the UK's Prescription Medicines Code of Practice Authority (PMCPA), after admitting that ...

Giusy Di Conza, head of research at small molecule cancer therapeutics firm iOnctura, said ADCs were “heralding a shift ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...